Docosahexaenoic acid

近日，据国家药品监督管理局官网公示，齐鲁制药ω-3脂肪酸乙酯90软胶囊（悦必妥®）获得国家药监局上市批准，用于在控制饮食的基础上，降低重度高甘油三酯血症(≥500mg/dL)成年患者的甘油三酯（TG）水平。 高甘油三酯血症是一种常见的血脂异常，也是心血管疾病的危险因素之一。传统降甘油三酯药物（如贝特类、烟酸类等）对肝肾功能不全人群、老年患者及孕产妇存在使用禁忌，并具有肌病和横纹肌溶解症等不良反应。对于混合型高脂血症患者，传统药物存在与他汀类药物联用限制，这极大程度地影响了患者的血脂治疗，故临床治疗迫切需要快速、安全、便捷的治疗方案。ω-3脂肪酸药物被全球多部指南、共识、科学声明推荐用于降低心血管疾病风险 。其中，ω-3脂肪酸乙酯90软胶囊以全新的作用机制、安全明确的降脂疗效、优良的药代动力学和药物相互作用机制，获得了国内外众多权威临床指南的一线推荐。 ω-3脂肪酸乙酯90软胶囊主要活性成分是鱼油中提取的EPA和DHA。ω-3脂肪酸乙酯90能抑制脂酰辅酶A，增加肝脏中线粒体和过氧化物酶体的β-氧化作用，减少肝脏中脂肪的生成，增加血浆脂蛋白脂肪酶的活性。EPA和DHA对其他脂肪酸的酯化具有抑制作用，因此本品可减少甘油三酯在肝脏中的合成。此外，本品不经肾脏代谢，具有良好的安全性和耐受性，可显著降低TG及心血管风险，并且可与他汀类药物安全联用。 齐鲁制药ω-3脂肪酸乙酯90软胶囊的获批上市，进一步富了齐鲁制药心血管产品管线，为广大高甘油三酯血症患者提供了更多治疗选择，进一步提高了药物可及性。 未来，齐鲁制药继续以患者为中心，瞄准临床急需和未被满足的重大需求，研发更多新药、好药，为推进健康中国建设持续贡献齐鲁力量。 撰稿：刘宝明、王荣荣 点击下方关键词 获取更多资讯  ↓↓ | 李燕总裁 | 全国人大代表 | | 研发综合实力百强 | 中国医药百强 |  | 伊鲁阿克 | 1类新药 | 患者招募 | | 社会责任企业 | 企业文化最佳实践企业 | 绿色发展奖 |  | 董事长的二十万个蛋糕 | 2023十大新闻 |

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.” The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576. About Lobe Sciences Ltd. Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia ® , a medical food designed to meet the needs of sickle cell patients globally. Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.